Biomarker-based immunoassays market set to reach $11.55 billion by 2030

The biomarker-based immunoassays market is projected to grow from $6.6 billion in 2025 to $7.37 billion in 2026, with North America leading and Asia-Pacific expected to expand fastest. The report points to cancer diagnostics, personalized medicine and AI-driven analysis as the main forces shaping demand through 2030.

Why it matters: - Biomarker-based immunoassays are central to early disease detection, cancer monitoring and personalized treatment decisions. - The market’s growth reflects rising demand for diagnostic tools that can support faster and more precise clinical decisions. - Cancer incidence is a major demand driver, with the World Health Organization projecting more than 35 million new cancer cases by 2050, up 77% from about 20 million in 2022.

What happened: - The Business Research Company published a 2026 market report on the global biomarker-based immunoassays market. - The market was valued at $6.6 billion in 2025 and is projected to reach $7.37 billion in 2026. - The report forecasts the market will rise to $11.55 billion by 2030. - The report was released June 29, 2026, in London. - A free sample is available here. - The full report is available here.

The details: - The market is expected to grow at a compound annual growth rate of 11.6% from 2025 to 2026. - The report projects a 11.9% CAGR through 2030. - Rising chronic disease prevalence is boosting demand for early diagnostic testing. - Expanding use of enzyme-linked immunosorbent assay, or ELISA, in clinical labs is supporting growth. - Hospital diagnostic infrastructure and laboratory networks are expanding. - Researchers are using more antibody-based detection methods. - Standardized biomarker identification techniques in biomedical studies are improving. - Personalized medicine and precision diagnostics are becoming a bigger focus. - Artificial intelligence and machine learning are increasingly being integrated into biomarker data analysis. - Multiplex and high-throughput immunoassay technologies are gaining adoption. - Point-of-care testing is expanding in remote healthcare settings. - Pharmaceutical research and drug discovery spending is adding demand. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region in the next period.

Between the lines: - The report points to a shift from traditional single-marker testing toward faster, more automated and data-driven workflows. - AI-driven interpretation, cloud-connected systems and robotic sample processing suggest diagnostics vendors are competing on speed, scale and data integration as much as on assay chemistry. - Growth in oncology and precision medicine is likely to keep biomarker testing tied closely to high-value clinical and research use cases.

What's next: - The report expects adoption to continue rising as clinical labs, researchers and point-of-care providers add multiplex, automated and AI-enabled testing tools. - Further growth will likely depend on how quickly healthcare systems expand diagnostics capacity and how broadly precision medicine moves into routine care. - The Business Research Company also highlighted new report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables.

The bottom line: - Biomarker-based immunoassays are moving from a niche diagnostic tool to a broader platform for cancer care, precision medicine and high-throughput testing.